Fenwick & West represented Audentes Therapeutics, Inc., (NASDAQ: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases, in its initial public offering of 5,000,000 shares of its common stock at a price to the public of $15.00 per share. As part of the offering, Audentes granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the offering price.
BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as joint book-running managers for the offering. Wedbush PacGrow acted as a co-manager.
The Fenwick transaction team included corporate partners Effie Toshav, Robert Freedman and James Evans, and associates Amanda Rose, Liz Federowicz, and Shiva Mirzanian.